Cargando…

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

BACKGROUND: Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple-negative breast cancers (TNBCs) reporting, at least six different molecular subtypes of TNBC namely Basal-like 1 (BL1), basal-like 2 (BL2)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bareche, Y, Venet, D, Ignatiadis, M, Aftimos, P, Piccart, M, Rothe, F, Sotiriou, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913636/ https://www.ncbi.nlm.nih.gov/pubmed/29365031 http://dx.doi.org/10.1093/annonc/mdy024

Ejemplares similares

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
por: Bareche, Yacine, et al.
Publicado: (2019)

Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis
por: Rothé, Françoise, et al.
Publicado: (2022)

The current use and attitudes towards tumor genome sequencing in breast cancer
por: Gingras, I., et al.
Publicado: (2016)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets
por: Sekiguchi, Masahiro, et al.
Publicado: (2020)

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients
por: Rothé, Françoise, et al.
Publicado: (2021)

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group
por: Maetens, Marion, et al.
Publicado: (2017)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling
por: Huang, Hao, et al.
Publicado: (2021)

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations()
por: Conforti, Fabio, et al.
Publicado: (2021)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
por: Buisseret, Laurence, et al.
Publicado: (2023)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer
por: Jiang, Ke, et al.
Publicado: (2021)

Integrated multiomic data analysis reveals the clinical significance of TXNIP and contributing to immune microenvironment in triple negative breast cancer
por: Gong, Han, et al.
Publicado: (2023)

Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer
por: Chiu, Alec M., et al.
Publicado: (2018)

Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors
por: Tang, Xiaojia, et al.
Publicado: (2023)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman, Michael L, et al.
Publicado: (2015)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Huang, Yunxia, et al.
Publicado: (2023)

Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy
por: Wang, Gang, et al.
Publicado: (2023)

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
por: Rothé, Françoise, et al.
Publicado: (2011)

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations
por: Nguyen, Bastien, et al.
Publicado: (2018)

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
por: Sonnenblick, Amir, et al.
Publicado: (2015)

A fuzzy gene expression-based computational approach improves breast cancer prognostication
por: Haibe-Kains, Benjamin, et al.
Publicado: (2010)

Multiomics integration-based molecular characterizations of COVID-19
por: Li, Chuan-Xing, et al.
Publicado: (2021)

Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?
por: Piccart, M, et al.
Publicado: (2011)

Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer
por: Yuan, Yinyin
Publicado: (2015)

Heterogeneity at the invasion front of triple negative breast cancer cells
por: Aw Yong, Koh Meng, et al.
Publicado: (2020)

Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer
por: Chen, Chen, et al.
Publicado: (2021)

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial
por: Sonnenblick, Amir, et al.
Publicado: (2015)

Embracing Integrative Multiomics Approaches
por: Rotroff, Daniel M., et al.
Publicado: (2016)

Integrative multiomics-histopathology analysis for breast cancer classification
por: Ektefaie, Yasha, et al.
Publicado: (2021)

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Integration of heterogeneous molecular networks to unravel gene-regulation in Mycobacterium tuberculosis
por: van Dam, Jesse CJ, et al.
Publicado: (2014)

Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Evaluation of triple negative breast cancer with heterogeneous immune infiltration
por: Quintana, Ángela, et al.
Publicado: (2023)

Multiomics: unraveling the panoramic landscapes of SARS-CoV-2 infection
por: Wang, Xin, et al.
Publicado: (2021)

Histologically resolved multiomics enables precise molecular profiling of human intratumor heterogeneity
por: Chen, Tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e87not3p9bdamn6jv1s2uc5dgo